ImmunityBio Reports Explosive Revenue Growth Amid Critical Financial Juncture

ImmunityBio, a biotechnology firm, has unveiled staggering commercial growth for its cancer therapy ANKTIVA. The company’s fiscal 2025 performance was marked by a near 700% surge in net product revenue, even as it continues to grapple with substantial net losses. Investor attention is now sharply focused on the details of its global commercialization strategy and how management intends to navigate its constrained liquidity position.

Clinical Progress and Pipeline Momentum

Beyond the financials, the company’s clinical development serves as a critical valuation driver. A significant milestone was reached in late February 2026, with the completion of patient enrollment for the pivotal QUILT 2.005 study. This trial is evaluating ANKTIVA in combination with BCG for bladder cancer patients.

Interim data released to date has been compelling, demonstrating a statistically significant advantage over standard therapy. At the six-month mark, 85% of patients receiving the combination treatment showed a complete response, compared to just 57% in the control group. The interim analyses also reported no emerging safety concerns.

Looking ahead, ImmunityBio is targeting a crucial regulatory submission. The company plans to file a Biologics License Application (BLA) in the fourth quarter of 2026, a move that could translate its clinical successes into more durable financial stability.

Financial Performance: A Tale of Two Trends

The figures, released ahead of an investor call scheduled for 1:30 PM Pacific Time today, paint a picture of rapid commercial traction contrasted with persistent financial challenges. For the full fiscal year 2025, ImmunityBio recorded net product revenue of approximately $113 million for ANKTIVA. The fourth quarter alone saw revenues hit $38.3 million, representing a 431% year-over-year increase, while the volume of goods sold skyrocketed by 750%.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Despite this explosive top-line growth, the bottom line remains deeply in the red. The company posted a net loss of about $351.4 million. Market observers are paying close attention to the balance sheet, where shareholders’ equity is negative and the cash runway is reported to be under one year. While management forecasts robust earnings growth and expects to reach profitability within a three-year horizon, the immediate priority is securing financing to fund ongoing operational expansion.

Global Regulatory Strategy Gains Traction

On the operational front, ImmunityBio is aggressively pursuing international market access. Within two years of its initial U.S. approval, ANKTIVA has now gained regulatory clearance in 33 countries. This list includes the United States, the United Kingdom, Saudi Arabia, and—following a recent decision by the European Commission in February 2026—all 27 European Union member states plus EFTA countries.

For the European market, the company has established a partnership with Accord Healthcare. The service provider will deploy a team of over 100 specialists to manage commercialization across the EU. ImmunityBio also secured a notable regulatory win in Saudi Arabia, where the local agency granted the world’s first approval for ANKTIVA in treating lung cancer. This decision expands the drug’s potential application beyond its initial bladder cancer indication.

Today’s investor call is expected to center on the specifics of the financing strategy for the coming quarters and the timeline for additional regulatory filings. The company stands at a pivotal point, needing to balance its remarkable commercial and clinical momentum with the imperative of strengthening its financial foundation.